Evidence map›Paper›PMID 37446144›Full record

ArticleInternational journal of molecular sciences2023

Selective Killing of BRCA2-Deficient Ovarian Cancer Cells via MRE11 Blockade.

Adel Alblihy, Reem Ali, Mashael Algethami, Alison A Ritchie, Ahmed Shoqafi, Shatha Alqahtani, Katia A Mesquita, Michael S Toss, Paloma Ordóñez-Morán, Jennie N Jeyapalan and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Adel AlblihyNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 3RD, UK.
Reem AliNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 3RD, UK.
Mashael AlgethamiNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 3RD, UK.
Alison A RitchieNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 3RD, UK.ORCID 0000-0002-5092-4979
Ahmed ShoqafiNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 3RD, UK.
Shatha AlqahtaniNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 3RD, UK.
Katia A MesquitaNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 3RD, UK.ORCID 0000-0001-9832-5548
Michael S TossNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 3RD, UK.
Paloma Ordóñez-MoránNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 3RD, UK.
Jennie N JeyapalanNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 3RD, UK.
Lodewijk DekkerNottingham Biodiscovery Institute, School of Pharmacy, University of Nottingham, Nottingham NG7 3RD, UK.ORCID 0000-0001-5247-3297
Martina SalernoNorth West Cancer Research Institute, School of Medical and Health Sciences, Bangor University, Bangor LL57 2UW, UK.
Edgar HartsuikerNorth West Cancer Research Institute, School of Medical and Health Sciences, Bangor University, Bangor LL57 2UW, UK.
Anna M GrabowskaNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 3RD, UK.ORCID 0000-0003-1507-921X
Emad A RakhaNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 3RD, UK.ORCID 0000-0002-5009-5525
Nigel P MonganNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 3RD, UK.
Srinivasan MadhusudanNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 3RD, UK.ORCID 0000-0002-5354-5480
University of Nottingham · GBBangor University · GBNottingham University Hospitals NHS Trust · GB

Funding

Naaz-Coker Ovarian Cancer Fellowship, University of Nottingham 01
6 · The paper itself

Abstract

The MRE11 nuclease is essential during DNA damage recognition, homologous recombination, and replication. BRCA2 plays important roles during homologous recombination and replication. Here, we show that effecting an MRE11 blockade using a prototypical inhibitor (Mirin) induces synthetic lethality (SL) in BRCA2-deficient ovarian cancer cells, HeLa cells, and 3D spheroids compared to BRCA2-proficient controls. Increased cytotoxicity was associated with double-strand break accumulation, S-phase cell cycle arrest, and increased apoptosis. An in silico analysis revealed Mirin docking onto the active site of MRE11. While Mirin sensitises DT40

Indexed as

DNA-Binding ProteinsOvarian NeoplasmsBRCA2 ProteinCell Line, TumorDNA RepairFemaleHeLa CellsHumansMRE11 Homologue ProteinPrecision MedicinePyrimidinonesThiones6-(4-hydroxyphenyl)-2-thioxo-2,3-dihydro-4(1H)-pyrimidinoneBRCA2 ProteinBRCA2 protein, humanDNA-Binding ProteinsMRE11 Homologue ProteinPyrimidinonesThionesBRCA2MRE11synthetic lethality

Identifiers

PMID37446144
PMCPMC10341502
OpenAlexW4382752503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.